Jubilant Therapeutics
Pennsylvania, United States · Biopharma, Biotechnology, Health Care
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutic
Key facts
- Headquarters
- Pennsylvania, United States
- Employees
- 12
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- www.jubilanttx.com
- Company page
Recent activity at Jubilant Therapeutics
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Daniel J. O’Connor, Chief Executive Officer
Verified email and direct lines for Jubilant Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Jubilant Therapeutics in the news
- Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026 - PR Newswire (Sep 15, 2026)
- Jubilant Therapeutics Announces Oral Presentation of Phase 1 Clinical Results for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting - AOL.com (Nov 10, 2026)
- Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models - BioSpace (Apr 13, 2023)
- Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer - PR Newswire (Dec 05, 2025)
- Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor - PR Newswire (Oct 25, 2024)
Companies similar to Jubilant Therapeutics
- Innovent Biologics (Innovent) · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- YS Biopharma · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Sino Biopharmaceutical · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Jubilant Therapeutics: questions and answers
What does Jubilant Therapeutics do?
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutic
Where is Jubilant Therapeutics headquartered?
Jubilant Therapeutics is headquartered in Pennsylvania, United States.
How many employees does Jubilant Therapeutics have?
Jubilant Therapeutics has about 12 employees.
Who leads Jubilant Therapeutics?
Daniel J. O’Connor is a Chief Executive Officer at Jubilant Therapeutics.
What is the latest news on Jubilant Therapeutics?
On Dec 2, 2025, Jubilant Pharmova Appoints Daniel J. O’Connor as Chief Executive Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy